Atlantic Council maps AI data supply chain risks for health and biopharma sectors

A new Atlantic Council report analyzes how health and biopharma firms navigate the AI data supply chain amid fragmented global regulations, covering seven data components and fourteen regulatory regimes in the US, EU, China, and India. The report highlights tensions between innovation and compliance, particularly around cross-border genomic data, but offers no new empirical findings. It signals growing policy focus on AI data governance in regulated industries.